Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand-name drug

Spravato price, strengths & recalls

Brand of esketamine (generic)

Pharmacies pay $1,288.12 for 3 vials of Spravato 84 mg dose kit pack this week, and from $854.37 to $1,288.12 across its 2 priced strengths and forms. Its official label last changed on September 24, 2026.

Brand
Pharmacies pay$1,288.12for 3 vials of 84 mg dose kit pack-0.1% in 4 weeks
Fair cash price
$1,491.84
Strengths
2
Makers
1
Updated
Nov 11

Spravato price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
56 mg dose kit pack Brand$427.19$854.37 / 2 vials+0.2%+8.1%
84 mg dose kit pack Brand$429.37$1,288.12 / 3 vials-0.1%+7.6%

Spravato vs generic esketamine

There is no generic version of Spravato on the market yet. Its last listed patent or exclusivity runs to February 18, 2040 - generics often follow, though court cases and settlements can move the date either way.

GenericEsketamine prices

Supply status: shortages & recalls

No shortage reportedChecked Nov 16, 2026
No ongoing recallsNone on record

What did you pay for spravato? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedSeptember 24, 2026
Version21 of 20
EffectiveSep 22, 2026
Read the label

These highlights do not include all the information needed to use SPRAVATO safely and effectively. See full prescribing information for SPRAVATO. SPRAVATO® (esketamine) nasal spray, CIII Initial U.S. Approval: 1970 (ketamine)

This drug has a boxed warning

WARNING: SEDATION; DISSOCIATION; RESPIRATORY DEPRESSION; ABUSE AND MISUSE; and SUICIDAL THOUGHTS AND BEHAVIORS

WARNING: SEDATION; DISSOCIATION; RESPIRATORY DEPRESSION; ABUSE AND MISUSE; and SUICIDAL THOUGHTS AND BEHAVIORS

See full prescribing information for complete boxed warning.

Risk for sedation, dissociation, and respiratory depression after administration. Monitor patients for at least two hours after administration. (

5.1,

5.2,

5.3)

Potential for abuse and misuse. Consider the risks and benefits of prescribing SPRAVATO prior to using in patients at higher risk of abuse. Monitor patients for signs and symptoms of abuse and misuse. (

5.4)

SPRAVATO is only available through a restricted program called the SPRAVATO REMS. (

5.5)

Increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. SPRAVATO is not approved for use in pediatric patients. (

5.6)

Sedation

Patients are at risk for sedation after administration of SPRAVATO

[see

Warnings and Precautions (5.1)].

Dissociation

Patients are at risk for dissociative or perceptual changes after administration of SPRAVATO

[see

Warnings and Precautions (5.2)].

Respiratory Depression

Respiratory depression has been observed in postmarketing experience

[see

Warnings and Precautions (5.3)].

Because of the risks of sedation, dissociation, and respiratory depression, patients must be monitored for at least 2 hours at each treatment session, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting

[see

Warnings and Precautions (5.1,

5.2,

5.3)].

Abuse and Misuse

SPRAVATO has the potential to be abused and misused. Consider the risks and benefits of prescribing SPRAVATO prior to use in patients at higher risk of abuse. Monitor patients for signs and symptoms of abuse and misuse

[see

Warnings and Precautions (5.4)].

Because of the risks of serious adverse outcomes resulting from sedation, dissociation, respiratory depression, abuse and misuse, SPRAVATO is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the SPRAVATO REMS

[see

Warnings and Precautions (5.5)].

Suicidal Thoughts and Behaviors

Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. SPRAVATO is not approved for use in pediatric patients

[see

Warnings and Precautions (5.6)].

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA211243 · Janssen Pharms
First approved
March 5, 2019 (7 years ago)
Latest approved change
September 17, 2026
Approved label
PDF, Oct 21, 2026
Generic makers
None on the market
Last patent listed
February 18, 2040
Exclusivity ends
January 17, 2028

Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.

Spravato questions

How much does spravato cost without insurance?

Pharmacies pay about $1,288.12 for 3 vials of spravato 84 mg dose kit pack ($429.37 per unit). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $1,491.84. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is there a generic for Spravato?

Yes: esketamine. Compare esketamine prices.

Is spravato in shortage?

No shortage is reported for spravato right now. We check the national shortage list every day.

Has spravato been recalled?

No recalls are on record for spravato.

When did the spravato label last change?

The official label was last updated on September 24, 2026 (version 21). See what changed.

Talk about spravato

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.